The company operates a pharmaceutical business that generated Rs. 25.1936 crore from its named Pharma Business segment in FY26, up from Rs. 20.861 crore in FY25, against total FY26 revenue of Rs. 132.3062 crore. In June 2026, it signed an agreement with GMBU e.V., a research organisation in Halle (Saale), Germany, to scale up commercial production of Astaxanthin, a natural antioxidant pigment used in nutraceuticals and aquaculture, at its research facilities in Hyderabad, after successful pilot-scale work. The company is funding this expansion through preferential share issues: 12 lakh shares were allotted to 18 non-promoter investors at Rs. 57 each, raising Rs. 6.84 crore, alongside 33.75 lakh warrants converted by promoter-group entities at Rs. 20 each, raising Rs. 5.06 crore. The non-promoter issue proceeds are earmarked for technology transfer from GMBU Germany, a land lease deposit at Siddipet, land development, consumables, pre-operative expenses, and quality control equipment, with deployment targeted before September 30, 2026. EBIT from the Pharma Business in FY26 was Rs. 1.2329 crore, with total net profit of Rs. 2.5566 crore and an EBITDA margin of 2.6495%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharma Business, Other operations. Small-cap pharmaceutical and biotech research company at a capital-raising stage
| ₹ crore · consolidated | FY19 | FY20 | FY21 |
|---|---|---|---|
| Revenue | 10 | 10 | 9 |
| EBITDA (ex other income) | (0) | (1) | (4) |
| margin % | (1.5) | (5.0) | (41.1) |
| Owners' profit | 0 | 0 | (4) |
| EPS, as reported (₹) | (0.03) | (0.35) | (4.62) |
| ROE % · ROCE % | (1.3) · 0.0 | (2.3) · (0.8) | (51.1) · (49.5) |
| Debt / equity (x) | 0.08 | 0.07 | 0.00 |
| Cash from operations | — | — | 2 |
| Capex | — | — | (0) |
| ₹ crore | Q2 FY21 | Q3 FY21 | Q4 FY21 | Q1 FY22 | Q2 FY22 | Q3 FY22 | Q1 FY23 | Q2 FY23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 2 | 3 | 4 | 2 | 1 | 1 | 1 |
| Profit before tax | (0) | (0) | (3) | (0) | 0 | (1) | (0) | (0) |
| Net profit | (0) | (0) | (3) | (0) | 0 | (1) | (0) | (0) |
| EPS (₹) | (0.21) | (0.26) | (4.05) | (0.18) | 0.39 | (0.77) | (0.11) | (0.19) |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharma Business | 5 | 47.0 |
| Financial Services | 0 | 3.5 |
| Investments | 0 | 0.1 |
| Foods | 4 | 39.1 |
| Trading in Shares | 1 | 10.3 |
| Total, before eliminations | 10 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| NOVELIX PHARMACEUTICALS LIMITE ◆ | 185 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · Newspaper publication of 32nd AGM notice and e-voting info submitted to BSE | compliance | minimal | — | — |
| 7 Sept 2026 · AGM Notice and Annual Report Web Link Shared with Shareholders | management changes | low | — | — |
| 7 Sept 2026 · Novelix Pharmaceuticals 32nd AGM notice on Sept 30, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Submission of annual report and 32nd AGM notice for FY 2025-26 | board shareholder meetings | medium | — | — |
| 31 Aug 2026 · Novelix 32nd AGM on 30 Sept 2026 via video conferencing | board shareholder meetings | low | — | — |
| 31 Aug 2026 · Promoter-group director appointed as Whole-Time Director for 5 years | management changes | medium | — | — |
| 29 Aug 2026 · Board approves AGM notice, books closure, new Whole-time Director from promoter group | board shareholder meetings | low | — | — |
| 25 Aug 2026 · Novelix board meet on Aug 29 for AGM notice, board report, and director appointment | board shareholder meetings | low | — | — |
| 20 Aug 2026 · Novelix Pharma leases land for Micro Algae Cultivation facility in Telangana | capex operations | medium | — | — |
| 13 Aug 2026 · Q1 FY26 Deviation Statement: No Variation in Fund Use | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|
| — |
| 24.92 |
| — |
| (3.3) |
| (3.3) |
| — |
| (9.5) |
| Jeevan Scientific Technology L | 162 | 18.2 | 2.23 | 15.8 | 1.4 | 2.4 | 5.1 | 21.5 |
| GlobalSpace Technologies Limit | 116 | 38.0 | 2.04 | 25.3 | 5.0 | 3.4 | 13.7 | 7.1 |
| Adeshwar Meditex Limited | 24 | 21.8 | — | — | — | — | — | — |
| Vanta Bioscience Limited | 13 | 3.0 | — | — | — | 0.0 | (29.0) | — |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 24.9 | 5.2 | 57 of 57 | 0% |
| ROCE | (3.3) | 8.0 | 61 of 69 | 12% |
| ROE | (3.3) | 9.4 | 54 of 59 | 9% |
| Debt / Equity | 0.0 | 0.1 | 21 of 59 | 66% |
| EBITDA margin | (9.5) | 21.5 | 54 of 57 | 5% |
| Revenue growth | (71.5) | 20.2 | 55 of 57 | 4% |
| Profit growth | (105.5) | 11.4 | 48 of 55 | 13% |
| Market cap | 185 | 261 | 41 of 71 | 43% |
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
